Friday 6 November 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue: +16.7%
EPS: +747.6%
Free cash flow: −4.76%
Total debt: −2.66%

Quarter to September 2026, against a year earlier

156.74 0.08 +0.05%

Follow ALNY

Alert me

Market cap: $21.0B
P/E: 7.9×
Fwd P/E: 13.5×
Dividend yield: —
F-score: 6/9
Altman Z: 7.30
Beneish M: −1.95
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alnylam Pharmaceuticals, Inc. (ALNY) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a P/S ratio of 4.2×. Over the past ten years it has ranged from 4.2× (November 2026) to 224× (August 2016) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ALNY/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Alnylam Pharmaceuticals, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ALNY/metrics/ps-ratio">Alnylam Pharmaceuticals, Inc. (ALNY) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	14.2×	5.97%
FY2024	13.4×	0.32%
FY2023	13.3×	(51.40%)
FY2022	27.4×	15.17%
FY2021	23.8×	(21.54%)
FY2020	30.3×	(47.05%)
FY2019	57.3×	(41.51%)
FY2018	97.9×	(26.27%)
FY2017	133×	89.34%
FY2016	70.1×	(63.55%)

Period	P/S ratio	Change
Sep 2026	6.6×	(21.32%)
Jun 2026	8.4×	(18.38%)
Mar 2026	10.3×	(27.55%)
Dec 2025	14.2×	(24.18%)
43 more quarters	Free account

Against its own ten years

Low 4.2× High 224×

Ten-year median 38.4×

Current reading's percentile 0

Company	P/S ratio
JAZZ Jazz Pharmaceuticals PLC compare	3.1×
INCY Incyte Corporation compare	4.0×
ALNY Alnylam Pharmaceuticals, Inc.	4.2×
EXEL Exelixis, Inc. compare	6.8×
BNTX BioNTech SE Sponsored ADR compare	7.9×
ASND Ascendis Pharma A/S compare	13.5×
BBIO BridgeBio Pharma, Inc. compare	15.5×
INSM Insmed, Inc. compare	15.6×
ROIV Roivant Sciences Ltd. compare	3,528×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Alnylam Pharmaceuticals, Inc. (ALNY) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ALNY

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ALNY

Stockrow Weekly